Research Analysts’ Recent Ratings Changes for Kymera Therapeutics (KYMR)

Several analysts have recently updated their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

• 11/8/2025 – Kymera Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/5/2025 – Kymera Therapeutics had its price target raised by analysts at HC Wainwright from $70.00 to $84.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Kymera Therapeutics had its price target raised by analysts at Barclays PLC from $60.00 to $70.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – Kymera Therapeutics had its price target raised by analysts at Wells Fargo & Company from $53.00 to $69.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Kymera Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $73.00 price target on the stock.
• 11/4/2025 – Kymera Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $73.00 price target on the stock.
• 11/4/2025 – Kymera Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $67.00 price target on the stock.
• 11/3/2025 – Kymera Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $90.00 price target on the stock.
• 11/3/2025 – Kymera Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $90.00 price target on the stock.
• 10/24/2025 – Kymera Therapeutics had its price target raised by analysts at B. Riley from $60.00 to $80.00. They now have a “buy” rating on the stock.
• 10/22/2025 – Kymera Therapeutics had its price target raised by analysts at BTIG Research from $59.00 to $75.00. They now have a “buy” rating on the stock.
• 10/21/2025 – Kymera Therapeutics is now covered by analysts at Mizuho. They set an “outperform” rating and a $81.00 price target on the stock.
• 10/20/2025 – Kymera Therapeutics was upgraded by analysts at Mizuho to a “strong-buy” rating.
• 10/17/2025 – Kymera Therapeutics had its price target raised by analysts at Citigroup Inc. from $60.00 to $80.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Kymera Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/1/2025 – Kymera Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $53.00 to $63.00. They now have an “outperform” rating on the stock.
• 9/30/2025 – Kymera Therapeutics had its price target raised by analysts at Truist Financial Corporation from $53.00 to $68.00. They now have a “buy” rating on the stock.
• 9/27/2025 – Kymera Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/18/2025 – Kymera Therapeutics had its price target raised by analysts at HC Wainwright from $60.00 to $70.00. They now have a “buy” rating on the stock.
• 9/17/2025 – Kymera Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $60.00 price target on the stock.
• 9/16/2025 – Kymera Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $60.00 price target on the stock.
• 9/16/2025 – Kymera Therapeutics is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $70.00 price target on the stock.

Insider Buying and Selling

In other news, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total value of $3,659,157.92. Following the transaction, the insider directly owned 109,992 shares of the company’s stock, valued at $6,755,708.64. The trade was a 35.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the sale, the chief financial officer owned 227,409 shares in the company, valued at approximately $11,370,450. This trade represents a 25.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 206,910 shares of company stock valued at $11,402,648. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.